The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III ...

Waystar announced a new set of AI-powered tools designed to perform a variety of tasks, including appealing denied claims. 1 ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco.